Blog
RSS FeedPosted by Michael Wonder on 21 Feb 2019
Pharmaceutical Benefits Scheme process improvements webinar information forum
21 February 2019 - The Department of Health will be hosting a webinar to provide industry, consumers and clinicians with ...
Posted by Michael Wonder on 20 Feb 2019
My Health Record opt-out doubles to 2.5 million people
20 February 2019 - The number of Australians who opted out of the My Health Record system doubled after the ...
Posted by Michael Wonder on 20 Feb 2019
Governments health reforms mean health fund members lose benefits
20 February 2019 - More than 50,000 members of Australia’s largest health fund Bupa will lose cover for key joint ...
Posted by Michael Wonder on 20 Feb 2019
Updates for patients and communities
20 February 2019 - After spending the fall listening to patient groups and exploring how other organisations have involved patients ...
Posted by Michael Wonder on 20 Feb 2019
NICE terminates appraisal of combination regimen for patients with advanced platinum-sensitive ovarian cancer
20 February 2019 - The treatment regimen is bevacizumab with carboplatin and gemcitabine hydrochloride and paclitaxel. ...
Posted by Michael Wonder on 20 Feb 2019
New drug landscape dominated by high cost medicines
19 February 2019 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, ...
Posted by Michael Wonder on 19 Feb 2019
My Health Record reflects 'new consensus', says CEO Tim Kelsey
19 February 2019 - The government's controversial My Health Record was part of a "new consensus" on digital health, said ...
Posted by Michael Wonder on 18 Feb 2019
Brexit: will Britons living in the EU still get health care?
18 February 2019 - If the UK leaves the EU without a deal, reciprocal health care arrangements will not automatically ...
Posted by Michael Wonder on 18 Feb 2019
Medicines for rare disorders
13 February 2019 - PHARMAC is working on policy and funding for medicines for rare disorders. ...
Posted by Michael Wonder on 18 Feb 2019
Decision on spinal muscular atrophy treatment Spinraza deferred
18 February 2019 - PHARMAC's decision to defer a decision on funding the only treatment for spinal muscular atrophy (SMA) ...
Posted by Michael Wonder on 16 Feb 2019
Alunbrig recommended by NICE for non-small-cell lung cancer
15 February 2019 - NICE has recommended the use of Alunbrig (brigatinib) for treating ALK-positive advanced non-small-cell lung cancer after ...
Posted by Michael Wonder on 15 Feb 2019
NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company
15 February 2019 - NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in ...
Posted by Michael Wonder on 15 Feb 2019
Medicines Matter – Pre-election focus on health and better access to new medicines
15 February 2019 - As the Parliament gears up for the Federal Budget and campaigning commences for the election, Medicines ...
Posted by Michael Wonder on 15 Feb 2019
EU, America and China will all get new medicines ahead of Britain after Brexit, drug company boss warns
14 February 2019 - David Meek, the CEO of Ipsen, warns Britain leaving the European Union has seen the country fall ...
Posted by Michael Wonder on 14 Feb 2019
Cystic fibrosis breakthrough: hope for British sufferers as life-saving drug talks resume
14 February 2019 - Britain's cystic fibrosis sufferers have received fresh hope of receiving a life-saving drug after officials agreed to ...